Back to rankings

The Ensign Group, Inc. (ENSG)

NEUTRAL
HealthcareMedical Care FacilitiesUnited States

Fundamental

68

Price

$178.50

Market Cap

$10.57B

Part 1 · What the company is worth

Overview

The Ensign Group, Inc. provides skilled nursing, senior living, and rehabilitative services. It operates through two segments: Skilled Services and Standard Bearer. The Skilled Services segment provides short and long-term nursing care services for patients with chronic conditions, prolonged illness, and the elderly; specialty care, such as on-site dialysis, ventilator care, cardiac, and pulmonary management; and standard services, such as room and board, special nutritional programs, social services, recreational activities, entertainment, and other services. The Standard Bearer segment leases post-acute care properties to healthcare operators. In addition, the company operates senior living units; and provides ancillary services consisting of digital x-ray, ultrasound, electrocardiograms, sub-acute services, dialysis, respiratory, and long-term care pharmacy and patient transportation to people in their homes or at long-term care facilities, as well as mobile diagnostics. The company operates healthcare facilities in Alabama, Alaska, Arizona, Colorado, Idaho, Iowa, Kansas, Oregon, Nebraska, Nevada, South Carolina, Tennessee, Texas, Utah, Washington, and Wisconsin. The company was incorporated in 1999 and is based in San Juan Capistrano, California.

No editorial profile for this company yet

Direct competitors

Who this company fights with for the same customers

No editorial profile for this company yet

No competitor list for this company yet.

Balance Sheet & Liquidity

Revenue

$5.46B

Trailing 12 months (through 6/30/2026)

Net Income

$379M

Trailing 12 months (through 6/30/2026)

Free Cash Flow

-

Total Equity

$2.23B

Total Liabilities

$3.23B

Current Ratio

1.21

Interest Coverage

59.99

Debt/EBITDA

4.25

Earnings Per Share

Revenue & Net Income

Free Cash Flow

Income Breakdown

Historical statement

Margins over time

Debt over time

How heavy the debt is

Growth grid

Growth — Revenue

Fair Value Estimation

Fairly Valued

Fair Value

$154.78

Current Price

$178.50

Margin of Safety

-15.3%

Fair Value Range

$100.60 - $208.95

Estimation Methods

Analyst Target:$220.00
DCF:$93.59
PE-based:$139.36
Graham Growth:$202.81
EPV:$75.66
Analyst Consensus:Strong Buy (10B / 2H / 0S)
Last Earnings Surprise:+2.16%

Valuation Metrics

P/E Ratio

28.11

ROE

15.4%

P/B Ratio

4.28

P/FCF

-

Gross Margin

20.3%

ROIC

7.6%

Profitability Radar

Value Creation (Economic Moat)

ROIC

7.6%

WACC

6.8%

ROIC − WACC

+0.8 pp

ROIC is roughly in line with the cost of capital — the company is barely covering its capital cost.

Fundamental Analysis Criteria

Passed (17)

  • EPS shows upward trend
  • EPS CAGR 8.64%
  • Price CAGR 24.07%
  • ROIC 7.6%
  • Debt/Equity ratio
  • Operating Margin 8.6%
  • Current Ratio
  • Interest Coverage
  • Debt/EBITDA
  • Return on Tangible Assets
  • Low reliance on intangibles
  • ROE 16.5%
  • Revenue Growth 5Y 16.1%
  • Analyst Consensus 83% Buy
  • Earnings Quality (OCF/NI) 1.61
  • Share Dilution 1.2%
  • Piotroski F-Score 5/9

Failed (7)

  • Gross Margin 20.3%
  • P/B Ratio 4.28
  • Price below Graham Number
  • DCF valuation (Overvalued)
  • Earnings Surprise avg 0.7%
  • PEG Ratio 2.02
  • Net Margin Trend 6.9% vs 7.0%

Unavailable (4)

  • P/FCF NaN
  • Dividend Payout NaN%
  • Positive Free Cash Flow
  • CapEx intensity

Piotroski F-Score

5/9

Mixed signals: some areas need attention

score
criteria

Earnings Quality

1.61

High quality: earnings backed by cash

Share Dilution

1.2%

Share count is stable

Governance

Executive Team

NameTitleAge
Mr. Barry R. PortCEO & Chairman of the Board51
Mr. Spencer W. BurtonPresident & COO46
Ms. Suzanne D. Snapper CPACFO, Executive VP & Director51
Mr. Chad A. Keetch J.D.Chief Investment Officer, Executive VP & Secretary47
Ms. Beverly B. WittekindExecutive VP & General Counsel60
Kevin ReesePresident of Keystone Healthcare Inc-

Audit Risk

7

Board Risk

5

Compensation Risk

7

Shareholder Rights Risk

2

Part 2 · The price and when to enter

This part won't tell you whether the company is worth owning: it helps you choose when to buy it, once the fundamentals have convinced you. Inside: technical analysis, potential, historical drawdowns, gamma exposure.

Latest News

Recent headlines for ENSG, sourced from Markets Gazette.

No recent news for ENSG.